Literature DB >> 7855056

Polylactide microparticles prepared by double emulsion/evaporation technique. I. Effect of primary emulsion stability.

N Nihant1, C Schugens, C Grandfils, R Jérôme, P Teyssié.   

Abstract

The process of microencapsulation of proteins by double emulsion/evaporation in a matrix of polylactide (PLA) can be divided into three successive steps: first, an aqueous solution of the active compound is emulsified into an organic solution of the hydrophobic coating polymer; second, this primary water-in-oil emulsion (w/o) is dispersed in water with formation of a double water-oil-water emulsion (w/o/w); third, the organic solvent is removed with formation of solid microparticles. This paper focuses on the effect of primary emulsion stability on the morphology and properties of polylactide microparticles loaded with bovine serum albumin (BSA) used as model drug. Depending on the stability of the primary emulsion, the internal structure of microparticles can be changed from a multivesicular to a matrix-like structure. Similarly, the average porosity can be controlled in a range from a few tenths of a micron to ca. 20 to 30 microns. This morphology control could find potential applications not only for the controlled drug delivery but also for the production of microporous particles intended for some specific applications, such as cell culture supports and chromatographic matrices. Although, the interplay of several processing parameters (polymer precipitation rate, polymer coprecipitation with interfacial compounds such as protein or surfactant, stirring rate...) may not be disregarded, this study also indicated that a high loading of a hydrophilic drug can only be expected from a stable primary emulsion. When the stability of the primary emulsion is such as to prevent formation of macropores (> 10 microns), the total pore volume is close to that of the originally dispersed aqueous drug solution.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855056     DOI: 10.1023/a:1018912426983

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  5 in total

1.  (D, L) polylactide microspheres as embolic agent. A preliminary study.

Authors:  P Flandroy; C Grandfils; J Collignon; A Thibaut; N Nihant; S Barbette; R Jerome; P Teyssie
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Preparation of poly (D,L) lactide microspheres by emulsion-solvent evaporation, and their clinical applications as a convenient embolic material.

Authors:  C Grandfils; P Flandroy; N Nihant; S Barbette; R Jérome; P Teyssié; A Thibaut
Journal:  J Biomed Mater Res       Date:  1992-04

3.  Encapsulation of water-soluble drugs by a modified solvent evaporation method. I. Effect of process and formulation variables on drug entrapment.

Authors:  R Alex; R Bodmeier
Journal:  J Microencapsul       Date:  1990 Jul-Sep       Impact factor: 3.142

4.  Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer.

Authors:  Y Ogawa; M Yamamoto; S Takada; H Okada; T Shimamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1988-04       Impact factor: 1.645

5.  Preparation and characterization of poly(styrene) microcapsules containing corrosion inhibitors.

Authors:  A Mac; D Negi; D Friend
Journal:  J Microencapsul       Date:  1989 Jul-Sep       Impact factor: 3.142

  5 in total
  13 in total

1.  Cephalexin microspheres for dairy mastitis: effect of preparation method and surfactant type on physicochemical properties of the microspheres.

Authors:  Wasana Chaisri; Wim E Hennink; Chadarat Ampasavate; Siriporn Okonogi
Journal:  AAPS PharmSciTech       Date:  2010-05-29       Impact factor: 3.246

2.  Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).

Authors:  Jahidur Rashid; Brijeshkumar Patel; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2017-02-07       Impact factor: 9.776

3.  A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle.

Authors:  M Tobío; J Nolley; Y Guo; J McIver; M J Alonso
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

4.  A polysorbate-based non-ionic surfactant can modulate loading and release of beta-lactoglobulin entrapped in multiphase poly(DL-lactide-co-glycolide) microspheres.

Authors:  J Rojas; H Pinto-Alphandary; E Leo; S Pecquet; P Couvreur; A Gulik; E Fattal
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

5.  Improving protein delivery from microparticles using blends of poly(DL lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers.

Authors:  M K Yeh; S S Davis; A G Coombes
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

6.  Structural analysis of microparticles by confocal laser scanning microscopy.

Authors:  A Lamprecht; U Schäfer; C M Lehr
Journal:  AAPS PharmSciTech       Date:  2000-06-23       Impact factor: 3.246

7.  Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.

Authors:  Amit Rawat; Quamrul H Majumder; Fakhrul Ahsan
Journal:  J Control Release       Date:  2008-03-21       Impact factor: 9.776

8.  Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin.

Authors:  Tanmoy Sadhukha; Swayam Prabha
Journal:  AAPS PharmSciTech       Date:  2014-05-16       Impact factor: 3.246

Review 9.  Biologics and their delivery systems: Trends in myocardial infarction.

Authors:  Matthew A Borrelli; Heth R Turnquist; Steven R Little
Journal:  Adv Drug Deliv Rev       Date:  2021-03-26       Impact factor: 17.873

10.  Propaedeutic study for the delivery of nucleic acid-based molecules from PLGA microparticles and stearic acid nanoparticles.

Authors:  G Grassi; N Coceani; R Farra; B Dapas; G Racchi; N Fiotti; A Pascotto; B Rehimers; G Guarnieri; M Grassi
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.